Lexicon Pharmaceuticals said on Friday that Danish drugmaker Novo Nordisk has entered into a licensing deal with the company ...

Lexicon Pharmaceuticals (LXRX) stock soars as the company inks a licensing deal worth up to $1B with Novo Nordisk (NVO) for ...

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...

Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and near-term milestone paymentsTHE WOODLANDS, Texas, ...

Novo Nordisk has licensed an oral obesity drug that works via an uncommon mechanism and may help patients maintain their ...

Investing.com -- Lexicon Pharmaceuticals , Inc. (NASDAQ: LXRX) shares surged 30% following the announcement of an exclusive license agreement with Novo Nordisk (NYSE: NVO) for its developmental drug ...

Novo Nordisk partners with Lexicon Pharmaceuticals for obesity drug LX9851 in deal worth up to $1B, including $75M upfront ...

Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...

Novo Nordisk's shares faced a significant decline due to competition and sales lag, prompting concerns about its market edge.

That very rally was somewhat bittersweet, though, as St. Louis’ center fielder, Victor Scott II, robbed Ty France of a ...

The next installment on March 30 is about how Jim Folger discovered a new way to bring coffee to the masses. This opened the ...

Retail investors lost millions from the fraud perpetrated by Trevor Milton, according to prosecutors in court documents from just two weeks ago. Milton late Thursday said he was pardoned by President ...